MedTrace Logo

Evaluation of a Screen and Treat Protocol for Influenza

NCT06207058 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-05-23

Study results available
· View outcomes & findings →

Summary

This study seeks to demonstrate that the laboratory can mitigate respiratory virus transmission in underserved populations by using laboratory data to identify communities at risk for increase vial activity (hot spots) and intervening with a test-to-treat model provides increased access to influenza diagnostics and treatment in vulnerable and underserved communities.

Conditions

Interventions

DRUG

Baloxavir Marboxil

Subjects testing positive for influenza will receive a dose of Baloxavir Marboxil orally, according to the dosing indicated in the package insert.

Sponsors & Collaborators

  • Tricore, Inc

    lead OTHER

Principal Investigators

  • Michael Crossey, MD, PhD · Medical Director, Tricore Research Institute

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2024-05-31
Completion
2024-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06207058 on ClinicalTrials.gov